

Lithium neurotoxicity mimicking rapidly progressive dementia

Andrea Mignarri · Elena Chini · Alessandra Rufa ·
Raffaele Rocchi · Antonio Federico ·
Maria Teresa Dotti

Received: 22 October 2012/Revised: 10 December 2012/Accepted: 22 December 2012/Published online: 11 January 2013
© Springer-Verlag Berlin Heidelberg 2013

Dear Sirs,

Lithium is currently used in the prophylaxis and treatment of depression and bipolar disorders. It is rapidly assimilated by gastrointestinal tract and mainly eliminated by the kidney. The narrow therapeutic range and the well-known adverse effects represent two important limits to its utilization in clinical practice: serum levels of lithium should be assessed every 3–6 months, since intoxication may determine renal failure, thyroid dysfunction, cardiac arrhythmias and neurotoxicity including tremor, nystagmus, ataxia, seizures and even coma [1]. Here we describe a case of insidious-onset lithium intoxication resembling a progressive neurodegenerative dementia and requiring differential diagnosis with Creutzfeldt-Jacob disease (CJD).

A 60-year-old Italian woman was recently referred to our Unit. She had been affected by bipolar disorder since adolescence, and had been receiving treatment with lithium carbonate (600 mg/day) for 15 years and olanzapine (5 mg/day) for 5 years. Serum lithium concentration had been regularly assessed and never revealed abnormalities. Moreover, there had been no recent variation of lithium dose. Apart of the psychiatric illness, her clinical history was unremarkable. In the last 2 months, the patient was noted to have decreased cognitive function associated with worsening ataxia and involuntary movements. Also, relatives referred that the patient had become distractible, dysphoric and irritable. On admission, neuropsychological

evaluation revealed she was deeply demented, almost speechless, giving erratic or delayed verbal responses to questions. She displayed poverty of thought, disorganization, and attentional impairment. No signs of psychosis were present. Neurological examination revealed ideomotor apraxia, gait ataxia, limb dysmetria and hand myoclonic movements. Routine blood tests were normal, including renal and thyroid function. Electrocardiogram did not reveal alterations. Electroencephalography (EEG) uncovered a significant background slowing with intrusion of biphasic and triphasic slow waves, compatible with cortical and subcortical dysfunction due to toxic/metabolic encephalopathy (Fig. 1a). Brain magnetic resonance imaging showed a chronic vascular encephalopathy with multiple post-ischemic gliotic changes in the periventricular and subcortical white matter. Cerebrospinal fluid analysis did not reveal abnormalities except for mildly increased levels of total-tau protein (347 pg/ml; normal <275) and phosphorylated-tau protein (65 pg/ml; normal <50). Assessment of serum lithium concentration revealed a marked increase at 2.45 mmol/l (therapeutic range 0.6–1.2). Subsequent lithium discontinuation led to a sharp normalization of serum lithium levels and a rapid improvement of cognitive function and ataxia, as well as disappearance of myoclonic jerks. The EEG performed 5 days after drug withdrawal showed partial recovery of background activity and marked decrease of the slow waves (Fig. 1b). On day 10, the patient was discharged with a normal neurological examination.

The evaluation of patients with rapidly progressive dementia represents one of the most binding challenges for neurologists [2]. In these patients, taking a drug history is at least as important as performing instrumental and invasive exams. As a matter of fact, a number of medications that are currently used to treat psychiatric and neurological diseases, such as lithium, sodium valproate, carbamazepine

A. Mignarri · E. Chini · A. Rufa · R. Rocchi · A. Federico ·
M. T. Dotti (✉)

Department of Medicine, Surgery and Neurosciences,
University of Siena, Viale Bracci 2, 53100 Siena, Italy
e-mail: dotti@unisi.it




Fig. 1 a The EEG at baseline shows slowing of background activity at 7 Hz, and intrusion of biphasic and triphasic slow waves with prevalent frontal expression. **b** Five days after drug withdrawal, the

EEG reveals improvement of background activity (from 7 Hz to 8 Hz) and significant decrease of the bihemispheric slow waves

and GABAergic drugs, can be responsible for clinical pictures resembling rapidly progressive dementia. Lithium toxicity has been described so far in 12 subjects as a reversible cause of subacute cognitive impairment mimicking CJD [3, 4]. The previously reported patients, aged 56–76 years, were long-term treated with therapeutic doses of lithium at the time of symptoms onset. Serum lithium levels were either toxic or within the therapeutic range. EEG was altered with widespread slowing and/or generalized periodic activity. In all cases, the prognosis was

favorable with full clinical recovery and EEG improvement after lithium discontinuation.

Our case report further underlines that lithium intoxication must also be suspected in long-term treated patients: in this respect, the causes of sudden variations of serum lithium levels remain to be elucidated. In our patient, the marked elevation of serum lithium levels helped to clarify the diagnosis, together with the EEG pattern and the clinical and electrophysiological improvement after drug withdrawal. However, clinicians must be aware that

lithium neurotoxicity causing subacute cognitive decline may occur also at therapeutic serum levels [3, 5, 6], and drug discontinuation should be tried in all the lithium-treated patients who develop rapidly progressive dementia. Furthermore, it is noteworthy that lithium toxicity can also involve the central nervous system in absence of systemic disturbances and straightforward precipitating events. In the present case, ischemic cerebrovascular disorder could have played a role in lithium neurotoxicity exposure: indeed, the presence of underlying neurologic disease may represent a risk factor, because of both the abnormal affinity for lithium and the diminished capacity for its removal in pathological brain tissue [7]. This aspect is worthy of further investigation in order to better understand the pathogenesis of lithium neurotoxicity.

Conflicts of interest None.

Ethical standard This study has been approved by the appropriate ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.

References

1. Dunne FJ (2010) Lithium toxicity: the importance of clinical signs. *Br J Hosp Med (Lond)* 71:206–210
2. Rosenbloom MH, Atri A (2011) The evaluation of rapidly progressive dementia. *Neurologist* 17:67–74
3. Kikyo H, Furukawa T (1999) Creutzfeldt-Jakob-like syndrome induced by lithium, levomepromazine, and phenobarbitone. *J Neurol Neurosurg Psychiatry* 66:802–803
4. Mouldi S, Le Rhun E, Gautier S, Devemy M, Destée A, Defebvre L (2006) Lithium-induced encephalopathy mimicking Creutzfeldt-Jakob disease. *Rev Neurol (Paris)* 162:1118–1121
5. Casanova B, de Entrambasaguas M, Perla C, Gómez-Siurana E, Benetó A, Burguera JA (1996) Lithium-induced Creutzfeldt-Jakob syndrome. *Clin Neuropharmacol* 19:356–359
6. Masmoudi K, Rosa A, Canaple S, Andrejak M (1996) Pseudo-Creutzfeldt-Jakob syndrome with long-term lithium use. *Thérapie* 51:688–690
7. Kemperman CJ, Gerdes JH, De Rooij J, Vencken LM (1989) Reversible lithium neurotoxicity at normal serum level may refer to intracranial pathology. *J Neurol Neurosurg Psychiatry* 52:679–680